Sopharma AD (SPH) Stock Overview
Produces, distributes, and exports pharmaceutical products in Europe, Bulgaria, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 5/6 |
| Financial Health | 4/6 |
| Dividends | 2/6 |
SPH Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more
Sopharma AD Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €7.50 |
| 52 Week High | €16.00 |
| 52 Week Low | €4.00 |
| Beta | 0.042 |
| 1 Month Change | -25.00% |
| 3 Month Change | n/a |
| 1 Year Change | 76.47% |
| 3 Year Change | 84.43% |
| 5 Year Change | 150.00% |
| Change since IPO | 200.00% |
Recent News & Updates
Recent updates
Shareholder Returns
| SPH | PL Pharmaceuticals | PL Market | |
|---|---|---|---|
| 7D | -1.3% | -2.0% | -1.5% |
| 1Y | 76.5% | -20.3% | 20.8% |
Return vs Industry: SPH exceeded the Polish Pharmaceuticals industry which returned -20.3% over the past year.
Return vs Market: SPH exceeded the Polish Market which returned 20.8% over the past year.
Price Volatility
| SPH volatility | |
|---|---|
| SPH Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 5.1% |
| Market Average Movement | 5.2% |
| 10% most volatile stocks in PL Market | 11.3% |
| 10% least volatile stocks in PL Market | 3.4% |
Stable Share Price: SPH's share price has been volatile over the past 3 months compared to the Polish market.
Volatility Over Time: Insufficient data to determine SPH's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1933 | 5,905 | Ognian Donev | www.sopharmagroup.com |
Sopharma AD produces, distributes, and exports pharmaceutical products in Europe, Bulgaria, and internationally. It offers Carsil to treat liver disease; Tempalgin, a painkiller; Analgin, a pain reliever; Tabex, a drug used for smoking secession; Tribestan, a drug used for stimulation of the male reproductive system; Broncholytin, which is used to suppress cough; Nivalin for use in the peripheral nervous system; Methylprednisolon for severe allergies and life-threatening conditions; Vitamin C; Valeriana to reduce the stress; and medical devices, such as gauzes, compresses, and dressing. The company also provides food supplements; medicinal and cosmetic products, including plasters, bandages, herbal cosmetics, and sanitary-hygiene products; concentrates for hemodialysis; and prescription medicines, and OTC and veterinary medical products.
Sopharma AD Fundamentals Summary
| SPH fundamental statistics | |
|---|---|
| Market cap | zł3.89b |
| Earnings (TTM) | zł300.32m |
| Revenue (TTM) | zł5.92b |
Is SPH overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SPH income statement (TTM) | |
|---|---|
| Revenue | лв2.63b |
| Cost of Revenue | лв2.00b |
| Gross Profit | лв631.15m |
| Other Expenses | лв497.62m |
| Earnings | лв133.52m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
Mar 31, 2026
| Earnings per share (EPS) | 0.25 |
| Gross Margin | 23.97% |
| Net Profit Margin | 5.07% |
| Debt/Equity Ratio | 50.1% |
How did SPH perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/03/14 03:11 |
| End of Day Share Price | 2026/03/12 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Sopharma AD is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.